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ABSTRACT
Since the emerging of the severe acute respiratory syndrome coronavirus-2 
(SARS-CoV-2) infection in Wuhan, China at the end of 2019, the coronavirus 
disease 2019 (COVID-19) has become pandemic for months. Due to fast increased 
number of the positive patients with COVID-19, SARS-CoV-2 is considered 
highly pathogenic virus with various clinical presentations. Apart from the 
typical respiratory symptoms, neurological complains in COVID-19 involving 
central and peripheral nervous systems have been reported. This paper aimed 
to review the neurological findings reported in patients with COVID-19. We 
qualitatively reviewed studies reporting COVID-19 patient(s) with neurological 
manifestations according to the recommendations of PRISMA statement.There 
were twelve studies included in this brief review. We found that patients with 
neurological findings were reported ranging from symptomatic complain of 
headache and dizziness to specific neurological diseases/syndromes, such 
as meningitis/encephalitis, acute cerebrovascular diseases, Guillain-Barré 
syndrome, and Miller Fisher syndrome. This review suggests the possible 
neurological involvement in COVID-19. We hope to raise the awareness of the 
health workers in taking care of the patients with COVID-19 and neurological 
diseases.
ABSTRAK
Sejak pertama kali muncul di Wuhan, Cina di akhir bulan Desember tahun 
2019, infeksi severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) 
atau coronavirus disease 2019 (COVID-19) telah menjadi pandemic selama 
berbulan-bulan. Karena cepatnya penambahan jumlah pasien COVID-19, 
SARS-CoV-2 dinyatakan sebagai pathogen poten dengan berbagai manifestasi 
klinis. Selain gejala pernapasan yang khas muncul pada COVID-19, penyakit 
ini juga dilaporkan menyebabkan gangguan saraf pusat dan perifer pada 
beberapa kasus. Makalah ini menelaah temuan neurologis yang dilaporkan 
pada pasien COVID-19. Makalah ini merupakan review kualitatif dari laporan/
dokumen yang memaparkan manifestasi neurologis pada pasien COVID-19 
sesuai dengan rekomendasi PRISMA. Terdapat 12 dokumen yang diikutkan 
dalam review ini. Temuan neurologis yang dilaporkan pada pasien COVID-19 
berkisar dari keluhan klinis seperti nyeri kepala dan pusing berputar hingga 
penyakit/sindrom neurologis spesifik seperti meningitis/encephalitis, penyakit 
serebrovaskular akut, sindrom Guillain-Barré, dan sindrom Miller Fisher. 
Dapat disimpulkan kemungkinan adanya keterlibatan masalah neurologis 
pada pasien COVID-19. Diharapkan agar setiap tenaga kesehatan yang merawat 
pasien COVID-19 dan penyakit saraf untuk selalu waspada.
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INTRODUCTION
Since it was firstly reported in 
Wuhan, China in December 2019, the 
novel coronavirus, as recently well-
known as severe acute respiratory 
syndrome coronavirus-2 (SARS-CoV-2), 
infection has spread throughout the 
world. As of April 26th, 2020, the cases 
update of coronavirus disease 2019 
(COVID-19) has reached the number 
of 2,989,420 infected people with case 
fatality rate of 6.91%, globally.1 Among 
other family of this single-stranded 
RNA virus infections, the world has 
experienced, the outbreaks of SARS-CoV 
in 2002 and MERS (middle east respiratory 
syndrome) in 2012, SARS-CoV-2 infection 
is the most devastating one that makes 
World Health Organization (WHO) 
announced it as a pandemic on March 
12th, 2020. In Indonesia, the number of 
COVID-19 patients keep rising up to 8,882 
positive cases with 8.36% case fatality 
rate in less than two months after the 
first confirmed case was firstly reported 
on March 2nd, 2020.2
Due to the fast spread of the virus, 
SARS-CoV-2 is considered as highly 
pathogenic with researches on its 
transmission, natural course and clinical 
presentation, high throughput diagnosis, 
and possible treatments regiment 
are currently advancing. Several 
studies on COVID-19 showed various 
spectrum of clinical presentations 
ranging asymptomatic infection; typical 
respiratory symptoms of fever, cough, 
fatigue, sputum production, shortness 
of breath, sore throat, myalgias or 
arthralgias; gastrointestinal symptoms 
of diarrhea, nausea, vomiting; and some 
neurological features as headache, 
impairment of consciousness, anosmia, 
and ageusia.3-5 Although the precise 
natural course and pathogenesis 
of COVID-19-induced neurological 
manifestations remained to be 
elucidated, some studies on neurological 
manifestations, complications, and 
syndromes in patients with COVID-19 
have been published. Therefore, all 
health workers should be aware that 
patients with COVID-19 might present 
with neurological manifestations or 
patients with neurological complains 
might be positive for COVID-19. Here, 
we presented a brief review on the 
neurological findings from studies and 
reports of COVID-19 patients to raise the 
awareness of the possible neurological 
involvement in this disease.
MATERIALS AND METHODS
This study is a qualitative systematic 
review following the recommendations 
of the Preferred Reporting Items 
for Systematic Reviews and Meta-
Analyses (PRISMA) statement (FIGURE 
1).6 The review protocol in this study 
was not previously registered. Our 
search methods were performed in 
MEDLINE (accessed via PubMed) to 
display electronic databases from 
December 1st, 2019 to April 24th, 2020. 
We systematically searched published 
articles by implementing the following 
keywords: central nervous system 
[Title/Abstract] OR peripheral nervous 
system [Title/Abstract] OR neurol*[Title/
Abstract] OR nerve*[Title/Abstract] 
OR encephal*[Title/Abstract] OR 
mening*[Title/Abstract] AND nCoV[all] OR 
2019-nCoV[all] OR new coronavirus[all] 
OR novel coronavirus[all] OR covid19[all] 
OR COVID-19[all] OR SARS-CoV-2[all]. 
All articles published in English were 
included. The authors also screened the 
references list of the included studies 
or relevant reviews to ensure other 
documents indexed by other indexing 
databases were included. Each article 
was screened and studied by two 
authors (MA and DBN) independently 
whether it met the inclusion criteria: 
any documents explaining neurological 
findings from patient(s) with COVID-19 
(including original article, case 
reports, case series, letter to editor or 
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correspondence), full article written in 
English, and published within December 
1st, 2019 to April 24th, 2020. The titles 
and abstracts of the yielded search were 
screened against the inclusion criteria, 
further full texts of any uncertain 
studies were obtained for screening. 
In regards to the recommendations 
of PRISMA statement, we excluded a 
systematic review regarding central 
nervous system manifestations of 
COVID-19. If there is any disagreement 
between the two authors, a third author 
was invited for discussion to resolve 
the problems. None of the authors 
were blind to the study titles, authors, 
and their institutions. The following 
data were extracted from the included 
studies: study authors, study designs, 
subjects studied, results in neurological 
findings both clinical and supporting 
examinations data, limitations, and 
level of evidence according to Oxford 
Centre for Evidence-Based Medicine 
levels of evidence.7 Quantitative analysis 
is performed whenever possible. Since 
we used secondary data that has been 
published, ethical clearance was not 
required for this study.
RESULTS
Systematic search results
Using the applied search methods, 
we found a total of 68 retrieved articles 
from the electronic database. After 
screening the articles by reading the 
abstracts, six articles were excluded due 
to its irrelevance and language (not in 
English). Full-texts were then assessed 
further to include only firstly reported 
COVID-19 patient(s)’ neurological 
findings. As a result, another 53 articles 
were eliminated. Of the nine remaining 
articles, we went through the detailed of 
each study, including its references list. 
From their references lists, we included 
three more eligible studies. Finally, 
there were twelve articles to answer our 
research question on the neurological 
findings in patients with COVID-19 
(FIGURE 1).
FIGURE 1. Preferred reporting items for systematic reviews and meta-
analyses (PRISMA) diagram flow of this study
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Among twelve included studies, 
three articles were original article with 
retrospective, observational methods, 
three articles were case reports or case 
series, and the other six articles were 
letter to editor or correspondence. 
All articles reported the neurological 
findings in patient(s) with COVID-19, 
both specifically and generally. In cases 
with specific neurological diseases 
or syndromes, we then categorized 
them into findings on meningitis/
encephalitis, acute cerebrovascular 
diseases, neuromuscular disease, and 
seizure. Apart from the abovementioned 
diseases or syndromes, the findings 
were categorized into other neurological 
findings. All extracted data were 
summarized in TABLE 1.
TABLE 1. Neurological findings reported in patients who were tested positive for COVID-19
Author/Year
Patients / 
Subjects and 
COVID-19 
diagnosis
Methods Neurological signs and symptoms
Supporting 
examinations 
findings
Limitations Level of Evidence
Mao et al.5 214 hospitalized 
patients with 
confirmed 
SARS-CoV-2 
infection by 
high throughput 
sequencing or 
Real-time PCR 
of throat swab 
specimens
Retrospective, 
observational, 
multi-center 
study
CNS manifestations: 
dizziness (16.8%), 
headache 
(13.1%), impaired 
consciousness 
(7.5%), acute 
cerebrovascular 
disease (2.8%), ataxia 
(0.5%), seizure (0.5%).
PNS manifestations: 
taste impairment 
(5.6%), smell 
impairment (5.1%), 
vision impairment 
(1.4%), nerve pain 
(2.3%).
Skeletal muscle injury 
(10.7%).
Laboratory findings:
Lower lymphocyte 
count, lower platelet 
count, and higher 
blood urea nitrogen 
level in patients with 
CNS symptoms.
Higher creatine 
kinase level, 
neutrophil count, 
higher C-reactive 
protein level, and 
higher D-dimer 
level in patients 
with skeletal muscle 
injury.
Ischemic stroke and 
cerebral hemorrhage 
were examined by 
head CT-scan. 
No CSF analysis, no 
electrophysiological 
studies (EEG, 
EMG, or ENMG), 
and no objective 
neurological 
examinations were 
reported. 
IIIb
Lu et al.17 304 COVID-19 
patients 
diagnosed 
according to 
Diagnosis and 
Treatment 
Protocol for 
COVID-19 (Trial 
Version 6) with 
positive nucleic 
acid detection. 
Retrospective, 
observational, 
multi-center 
study
Encephalopathy / 
altered consciousness 
/ mental status (2.6%), 
traumatic brain 
injury (0.3%), acute 
cerebrovascular 
disease (0.98%)
No reports on the 
laboratory findings 
between patients 
with and without 
neurological 
symptoms.
No EEG 
examinations and no 
further longitudinal 
evaluation on 
seizure were 
recorded.
IIIb
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Moriguchi et al.8 A 24-year-old 
male who was 
tested positive 
for SARS-CoV 2 
RNA in CSF.
Case Report Headache, 
generalized 
fatigue, fever, sore 
throat, altered 
consciousness, and 
generalized seizure 
(in chronological 
order over 9 days).
Neurological 
examinations: 
comatose (GCS 
E4V1M1), neck 
stiffness.
Laboratory findings: 
Increased WBC 
(neutrophilia 
with relative 
lymphopenia), 
increased C-reactive 
protein.
Imaging: 
Chest X-ray: negative 
finding
Head CT-scan: no 
brain edema
Chest CT-scan: small 
ground glass opacity 
on right superior 
lobe and bilateral 
inferior lobes
Brain MRI: 
hyperintensity 
along the wall of 
inferior horn of right 
lateral ventricle 
(DWI); hyperintense 
signal changes in 
the right mesial 
temporal lobe and 
hippocampus with 
slight hippocampal 
atrophy (FLAIR).
CSF analysis: 
opening pressure 
> 320 mmH2O, cell 
count 12/uL (10 MN, 
2 PMN), positive for 
SARS-CoV 2 RNA 
using RT-PCR.
No EEG examination 
and no final 
outcome was 
reported
IV
Poyiadji et al.18 A female in the 
late fifties with 
positive SARS-
Cov-2 nucleic 
acid in her 
nasopharyngeal 
swab tested 
using Real-Time 
PCR.
Case Report 
(Images in 
Radiology)
Cough, fever, altered 
mental status (over 
3 days)
Laboratory findings: 
Influenza negative.
CSF analysis: 
negative for 
bacterial culture and 
HSV-1, HSV-2, VZV, 
and West Nile virus.
Head CT-scan: 
symmetric 
hypoattenuation 
within bilateral 
medial thalami 
with normal CT 
angiogram and 
venogram.
Brain MRI: 
hemorrhagic rim 
enhancing lesions 
within bilateral 
thalami, medial 
temporal lobes, and 
subinsular regions.
No complete 
neurological 
examinations, no 
complete laboratory 
findings, no final 
outcome was 
reported.
IV
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Gutierrez-Ortis 
et al.16
A 50 year-old 
and 39 year-old 
male patients 
with positive 
SARS-CoV-2 from 
oropharyngeal 
swabs tested 
with Real-Time 
PCR.
Case reports Patient 1 (50 y.o, 
male)
Symptoms: cough, 
malaise, low back 
pain, fever, vertical 
diplopia, perioral 
paresthesia, gait 
instability (in 
chronological 
order in over 5 
days). Neurological 
examinations: normal 
consciousness, no 
facial weakness, 
perioral paresthesia, 
no motoric and 
sensoric deficits, 
broad-based ataxic 
gait, no dysmetria, 
absent deep 
tendon reflexes 
in all extremities, 
right internuclear 
ophthalmopharesis 
and right fascicular 
oculomotor palsy. 
Patient 2 (39 y.o, 
male)
Symptoms: diarrhea, 
low-grade fever, 
general weakness, 
diplopia, ageusia.
Neurological 
examinations: normal 
consciousness, 
bilateral abducens 
palsy, no motoric 
and sensoric deficits, 
absent deep tendon 
reflexes in all 
extremities, no gait 
instability or ataxia, 
no dysmetria.
Patient 1
Laboratory findings: 
lymphopenia, 
elevated C-reactive 
protein level, 
antibody to 
ganglioside GD1b-
IgG.
CSF analysis: 
opening pressure 
110 mmH2O, WBC 
0, protein 80 mg/
dl, glucose 62 mg/
dl, normal cytology, 
sterile culture, 
negative serologies, 
and negative for 
SARS-CoV2.
Chest X-ray: within 
normal limit
Head CT-scan: within 
normal limit
Patient 2
Laboratory findings: 
leukopeni.
CSF analysis: 
opening pressure 
100 mmH2O, WBC 2/
uL, protein 62 mg/
dl, glucose 50 mg/
dl, normal cytology, 
sterile culture, 
negative serologies, 
and negative for 
SARS-CoV2.
Chest X-ray: within 
normal limit
Head CT-scan: within 
normal limit
No 
electrophysiological 
studies were 
reported
IV
Ye et al.9 A Wuhan male 
detected positive 
for SARS-CoV-2.
Letter to editor/
Case report
Symptoms: fever, 
shortness of breath, 
myalgia, altered 
consciousness 
(confusion).
Neurological 
examinations: 
Positive meningeal 
irritation signs 
(nuchal rigidity, 
Kernig sign, 
Brudzinsky sign) and 
positive pathological 
reflex in lower limbs.
Laboratory findings: 
leukopenia with 
lymphopenia.
CSF analysis: 
opening pressure 
220 mmH2O, WBC 1/
uL, protein 27 mg/
dl, glucose 56 mg/dl, 
ADA 0.17 U/l.
Head CT-scan: within 
normal limit
Chest CT-scan: 
multiple subpleural 
ground glass 
opacities
No complete 
patient’s identity, no 
final outcome, and 
no explanation from 
which specimen 
positive SARS-CoV-2 
detection were 
reported.
IV
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Helms et al.12 58 patients 
with severe 
COVID-19 who 
were positive 
for SARS-
Cov-2 reverse-
transcriptase 
PCR from 
nasopharyngeal 
swab.
Letter to editor/
Case series
Positive CAM-ICU 
(65%), agitation 
(69%), corticospinal 
tract signs: enhanced 
tendon reflexes, 
ankle clonus, bilateral 
pathological reflexes 
in lower limbs 
(67%), dysexecutive 
syndromes: 
inattention, 
disorientation, poorly 
organized movement 
in response to 
command (36%)
Brain MRI 
(13 patients): 
leptomeningeal 
enhancement 
(62%), perfusion 
abnormalities 
(100%), cerebral 
ischemic stroke 
)23%).
CSF analysis (7 
patients):
Oligoclonal band 
with the same 
pattern in serum 
(29%), elevated IgG 
and protein level 
(14%), low albumin 
level (57%), negative 
SARS-CoV-2 RT PCR 
(100%)
No specific 
explanation on 
patients who 
underwent lumbar 
puncture and no 
final outcome were 
reported.
IV
Duong et al.10 A 41 year-old 
female who was 
tested positive 
for COVID-19
Letter to editor/
Case report
Symptoms: headache, 
fever, new-onset of 
seizure.
Neurological 
examinations: 
worsening 
encephalopathy 
(disorientation, 
hallucinations, 
lethargic), 
neck stiffness, 
photophobia, no 
motoric and sensoric 
deficit.
Laboratory findings: 
no abnormality 
reported, negative 
HSV PCR
CSF analysis:
WBC 70 (100% 
lymphocyte), RBC 65, 
protein 100, glucose 
120.
Head CT-scan: within 
normal limit
Serial chest X-ray: 
normal
Chest CT-scan: 
normal
No CSF analysis 
for SARS-CoV-2, no 
explanation from 
which specimen 
positive SARS-CoV-2 
detection were 
reported.
IV
Yin et al.11 A 64 year-old 
male in Wuhan 
who was tested 
positive for 2019-
nCoV nucleic 
acid from throat 
swab
Letter to editor/
Case report
Symptoms: fever, 
cough, insomnia, 
muscle soreness, 
lethargic, and 
unresponsive.
Neurological 
examinations: poor 
mental state, altered 
consciousness 
(lethargic, irritable), 
speech dissociation, 
positive pathological 
reflexes in bilateral 
lower limbs, positive 
meningeal signs (neck 
stiffness, Brudzinski 
sign).
Laboratory findings: 
normal WBC, 
slight increase in 
C-reactive protein 
level.
CSF analysis: 
colorless, clear, 
opening pressure 
200 mmH2O, WBC 1/
uL, protein 27.5 mg/
dl, glucose 56.5 mg/
dl, negative for 2019-
nCoV nucleic acid.
Head CT-scan: 
no significant 
abnormalities
Chest CT-scan: 
multiple ground-
glass opacities with 
multiple fibrous 
cord-like shadows in 
both lungs. 
IV
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Zhao et al.14 A 61 year-old 
woman who was 
tested positive 
for SARS-
CoV-2 using 
RT-PCR from 
oropharyngeal 
swab specimen
Correspondence/
Case report
Symptoms: acute. 
progrssive weakness 
in both legs, severe 
fatigue, followed by 
fever and cough after 
15 days.
Neurological 
examination (on 
arrival): progressive 
symmetrical 
weakness and 
areflexia in both legs, 
decreased sensoric 
function in distal 
extremities.
Laboratory findings: 
lymphopenia, 
thrombocytopenia.
CSF analysis: WBC 
5/uL, protein 124 
mg/dl.
NCS: delayed distal 
latencies and absent 
F-waves in early 
course, supporting 
demyelinating 
neuropathy.
No clear causality 
between SARS-CoV-2 
infection and GBS, 
no microbiological 
testing on admission 
were reported
IV
Toscano et al.15 5 patients who 
were positive 
for COVID-19: 
4 patients 
had positive 
nasopharyngeal 
swab of SARS-
CoV-2 and 1 
patient had 
positive serologic 
test for SARS-
CoV-2.
Letter to Editor/
Case series
Symptoms: four 
patients had lower-
limb weakness and 
paresthesia, one 
patient had facial 
diplegia followed 
by ataxia and 
paresthesia.
Neurological 
examinations: 
four patients had 
generalized flaccid 
tetraparesis/ 
tetraplegia evolved 
in period of 36 
hours until 4 days, 
three patients 
received mechanical 
ventilation.
CSF analysis: 
normal protein level 
(40%), normal WBC 
(100%), negative 
antiganglioside 
antibody (100%).
NCS and EMG 
(consistent with 
GBS): low compound 
muscle action 
potential (100%), 
prolonged motor 
distal latencies 
(40%), fibrillation 
potentials early 
(60%) late (20%).
Brain MRI: 
enhancement of 
bilateral facial nerve 
(20%)
Spinal MRI: 
enhancement of 
caudal nerve roots 
(40%)
No detailed 
laboratory findings 
were reported
IV
Li et al.21 221 patients with 
positive throat 
swab of SARS-
CoV-2 using 
RT-PCR
Single-center, 
retrospective, 
observational 
study
Acute ischemic stroke 
(5%), cerebral venous 
sinus thrombosis 
(0.5%), cerebral 
hemorrhage (0.5%)
Laboratory findings: 
increased WBC, 
neutrophilia, 
lymphopenia, low 
platelet count, 
increased C-reactive 
protein level, 
increased D-dimer 
level, increased AST 
level, increased 
blood urea nitrogen 
level, and increased 
creatinine level.
Head CT-scan 
was performed 
to establish the 
diagnosis of 
cerebrovascular 
diseases.
No other 
neurological 
manifestations were 
reported
IIIb
SARS-CoV-2: Severe Acute Respiratory Syndrome-Coronavirus-2; PCR: Polymerase Chain Reaction; CNS: Central Nervous System; CT-scan: 
Computed Tomography-scan; CSF: Cerebrospinal Fluid; EEG: Electroencephalography; EMG: Electromyography; ENMG: Electroneuromyography; 
GCS: Glasgow Coma Scale; WBC: White Blood Cell Count; MRI: Magnetic Resonance Imaging; DWI: Diffusion Weighted Images; FLAIR: Fluid-
attenuated Inversion Recovery; ADA: Adenosine Deaminase; CAM-ICU: Confusion Assessment Methods – Intensive Care Unit; NCS: Nerve 
conduction study; GBS: Guillain-Barré Syndrome; AST: Aspartate aminotransferase.
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Neurological findings on meningitis 
and encephalitis in patients with 
COVID-19
In this study, we found four reports 
on four positive COVID-19 patients with 
meningoencephalitis findings.8-11 All 
cases showed fever and consciousness 
disturbance, with only three of them 
were preceded by respiratory complains, 
such as shortness of breath or cough.9-11 
In neurological examination, all cases 
showed altered consciousness, fever, 
and positive meningeal irritation signs. 
Only one case that reported generalized 
seizure.8 In this case, brain MRI was 
performed showing abnormalities in 
patient’s right mesial temporal lobe and 
hippocampus. All patients underwent 
lumbar puncture with opening pressure 
of more than 20 mmH2O in three 
studies8,9,11 and all CSF analyses showed 
relatively normal cell count, protein 
level, and sugar level. Of the four cases, 
only one study showed negative throat 
swab of SARS-CoV-2 despite the presence 
of respiratory symptoms but positive 
CSF SARS-CoV-2.8 However, one case 
showed positive throat swab of SARS-
CoV-2 despite the absence of respiratory 
complains but negative CSF SARS-CoV-2.10 
Follow up for these cases showed that the 
neurological symptoms of three patients 
with positive throat swab of SARS-CoV-2 
improved following their recovery from 
the respiratory distress or after being 
given hydroxychloroquine.9-11
Neurological findings on acute 
cerebrovascular diseases in patients 
with COVID-19
There were three included studies in 
this review that reported the incidence 
of acute cerebrovascular diseases in 
patients with positive SARS-CoV-2 from 
throat swab: 5.17%,12 5.9%,13 and 2.8%5. 
All these studies reported that most of 
the patients with acute cerebrovascular 
diseases were suffered from severe 
COVID-19. All these patients underwent 
brain imaging of head CT-scan or brain 
MRI to establish their diagnoses of acute 
cerebrovascular diseases following focal 
neurological symptoms or unexplained 
encephalopathic features. Most of the 
cerebrovascular diseases reported were 
ischemic stroke, others were cerebral 
hemorrhage and cerebral venous 
sinus thrombosis. In two studies,  they 
reported increased white blood cell count 
(WBC), neutrophilia with lymphopenia, 
increased C-reactive protein level, 
increased D-dimer level, increased 
blood urea nitrogen level, and increased 
creatinine level were the laboratory 
findings in COVID-19 patients who were 
susceptible for having cerebrovascular 
diseases.5,13
Neurological findings on 
neuromuscular diseases in patients 
with COVID-19
Our search found three included 
studies that reported specific 
neuromuscular diseases in COVID-19 
patients. Two studies reported Guillain-
Barré syndrome (GBS) and one study 
reported Miller Fisher syndrome and 
polyneuritis cranialis in COVID-19 
patients.14-16 Zhao et al.14 reported a case 
of GBS in which the classic neurological 
symptoms of GBS with acute progressive 
limbs weakness and distal paresthesia 
preceding the characterized respiratory 
symptoms of COVID-19. Toscano et al.15 
reported five cases of GBS with initial 
symptoms of lower limb weakness and 
paresthesia in four patients and facial 
diplegia in another patient that following 
the onset of COVID-19 symptoms ranged 
from 5 to 10 days. Gutiérrez-Ortiz et al.16 
reported a patient with classical triad of 
Miller-Fisher: ophthalmoplegia, ataxia, 
and limbs areflexia after developing 
fever, cough, malaise, and headache; and 
another patient with bilateral abducens 
palsy and ageusia after presenting 
with low-grade fever and diarrhea. All 
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patients were tested positive for SARS-
CoV-2 from their throat swabs, except 
for one case with GBS whose SARS-
CoV-2 PCR were negative but positive 
for the virus serologic test.15 All patients 
underwent lumbar puncture, with most 
results showed marked increased in CSF 
protein level (TABLE 1). Only studies 
reporting GBS patients reported the 
nerve conduction study whose results 
were consistent with demyelinating 
neuropathy and axonal variant.14,15 In 
laboratory findings, antiganglioside 
antibodies were found negative in all 
the tested samples in GBS patients and 
positive for antibody GD1b-IgG in a 
patient with Miller-Fisher syndrome.15,16 
All patients in these reports, except for 
the one with polyneuritis cranialis, 
were treated using intravenous 
immunoglobulin. During the follow up, 
only two patients showed poor outcomes 
while the other patients resolved.15,16
Neurological findings on seizure in 
patients with COVID-19
We found two included studies that 
reported about seizure. A study reported 
the seizure incidence of 0.5% as one of the 
neurological manifestations in patients 
who were positive for SARS-CoV-2 
from throat swab specimen.5 However, 
this report was only based on clinical 
presentation of the patient without 
any further explanation regarding the 
seizure semiology or past history of 
epilepsy and further examinations of 
EEG (electroencephalography) or other 
brain imaging. In another study, it was 
reported that no new-onset seizure 
or status epilepticus following the 
diagnosis of COVID-19 in 304 patients.17 
Two seizure-like events were seen in 
patients with acute stress reaction and 
hypocalcemia that resolved after being 
given antianxiety and calcium correction 
treatments, respectively. Furthermore, 
this study highlighted the possibility 
for COVID-19 patients, particularly the 
ones with severe infections, for having 
acute symptomatic seizures as they have 
substantial risk factors such as hypoxia, 
shock, sepsis, multiorgan dysfunction 
syndrome, imipenem use, acute 
cerebrovascular disease, electrolyte 
imbalance, etc.
Other neurological findings in patients 
with COVID-19
In a study   reported  by  Mao et 
al.5 other than the above-mentioned 
neurological manifestations, some of 
these symptoms should be put into 
account: dizziness (16.8%), headache 
(13.1%), impaired consciousness 
(7.5%), ataxia (0.5%), taste impairment 
(5.6%), smell impairment (5.1%), vision 
impairment (1.4%), nerve pain (2.3%), 
and skeletal muscle injury (10.7%). This 
study also found increased creatinine 
kinase level in COVID-19 patients with 
skeletal muscle complains, regardless 
the severity. In other study, a case about 
acute necrotizing encephalopathy was 
reported from a female in her late 50’s 
with acute fever, cough, and altered 
mental status.18 Her throat swab was 
positive for SARS-CoV-2 nucleic acid. Her 
brain MRI confirmed the hemorrhagic 
rim enhancing lesions in bilateral 
thalami, medial temporal lobes, and 
subinsular regions. This report showed 
the rare complication of acute necrotizing 
encephalopathy that might be associated 
with SARS-CoV-2 infection. In severe 
COVID-19 patients with intensive care 
treatments, some neurologic signs 
that can be found in these patients 
are delirium with positive Confusion 
Assessment Methods – Intensive Care 
Unit (44%), agitation (69%), corticospinal 
tract signs (67%), and dysexecutive 
syndrome (24%).12
DISCUSSION
Our results showed the various 
neurological findings from patients with 
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COVID-19 reported in several studies 
suggesting the possible neurological 
involvement of the disease. However, the 
mechanisms on how SARS-CoV-2 could 
reach the central or peripheral nervous 
system are still widely studied. A study 
showed that angiotensin-converting 
enzyme-2 (ACE2) was found as the 
functional receptor for SARS-CoV-2, 
sharing the same receptor as SARS-CoV.19 
ACE2 is widely distributed in human 
body, including epithelial cells of alveoli, 
nasal mucous, gastrointestinal tracts, and 
also endothelial cells of the brain.20 As its 
functional receptors are ubiquitously 
distributed throughout the human body, 
SARS-CoV-2 infections may show various 
clinical presentations, including nervous 
system manifestations.
The neuroinvasion potential of SARS-
CoV-2 has been considered. This virus 
might ascend to reach the central nervous 
system (CNS) through olfactory nerves 
causing anosmia and its inflammatory 
immune response may affect the taste 
buds leading to ageusia.4,16,21 It might 
explain the invasion of SARS-CoV-2 to 
the central nervous systems. However, 
our study found that out of twenty 
COVID-19 patients who underwent 
lumbar puncture for CSF analyses due 
to the presenting neurological signs and 
symptoms, only eleven samples were 
further tested for SARS-CoV-2 nucleic 
acid with only one case was reported 
positive for SARS-CoV-2.8-12,14-18 This 
patient was tested negative for SARS-
CoV-2 from his nasopharyngeal swab 
sample but positively tested for SARS-
CoV-2 from his CSF sample,8 while the 
other cases were reported otherwise.
It might be due to the low viral titer in 
CSF and the SARS-CoV-2 dissemination 
is transient showed by the undetected 
anti-SARS-CoV-2 IgM and IgG in CSF 
sample of the COVID-19 patient.9 The 
exact mechanisms of immune response 
to SARS-CoV-2 is still widely studied 
since people may react differently to 
the disease, leading to mild COVID-19 
manifestations or critical/severe cases 
that often lead to mortality. Apart from 
the highly deleterious effect of the virus 
itself, several hypotheses regarding the 
immune responses in COVID-19 include 
the hyperinflammation that resemble 
cytokine release syndrome/cytokine 
storm in severe COVID-19 patients, 
the increased coagulopathy that might 
contribute to the fatality of COVID-19, 
the different of IgG and IgM levels 
among COVID-19 patients according 
to the disease severities, and possible 
autoimmune response that might trigger 
delayed complications from initial 
symptoms.22-24 All cases in our study 
reported that the neurological signs 
and symptoms were developed during 
acute phase of the disease, only day(s) 
since the initial fever and cough (TABLE 
1). Further investigation is necessary to 
elucidate the role of immune response 
to COVID-19 in the development of 
neurological manifestations.
All the COVID-19 patients who were 
reported with specific neurological 
manifestations underwent supportive 
examinations to confirm the diagnosis. 
For instance, patients with meningitis/
encephalitis showed the supporting 
clinical examinations of fever, altered 
consciousness, and CSF analysis 
that supported  the  findings  of 
viral infection.8-11 All patients with 
cerebrovascular diseases were found 
with focal or global neurological 
deficits and confirmed with cerebral 
imaging, such as head CT-scan or 
cerebral MRI.5,12,13 Patients that had 
cerebrovascular diseases were reported 
to have severe COVID-19 manifestations, 
higher serum D-dimer level, higher WBC 
with neutrophilia and lymphopenia, 
and higher C-reactive protein level.5,13 
Patients that were reported with 
neuromuscular diseases, such as GBS, 
Miller Fisher syndrome, and polyneuritis 
cranialis, showed typical symptoms of 
the diseases, underwent CSF analysis 
that mostly showed increased protein 
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level, electrophysiological studies to see 
the findings to support peripheral nerve 
disease, and mostly received intravenous 
immunoglobulin therapy.14-16 Although 
only few cases of new-onset seizure 
were reported, clinicians should always 
be cautious to the COVID-19 patients that 
showed potential risk factors for seizure, 
such as hypoxia, shock, sepsis, and 
electrolyte imbalance.17 Only patients 
that reported in case series, case reports, 
letter to editor, or correspondence 
that were examined thoroughly from 
its clinical, laboratory, and imaging 
findings. The included retrospective, 
observational studies that involved 
many patients did not report the full 
work up of the patients, except all 
patients reported with cerebrovascular 
diseases were established with head CT-
scan or brain MRI.
This review suggested the possible 
neurological involvement in patients 
with COVID-19. The neurological 
findings ranging from symptoms such 
as headache and dizziness to some 
established specific neurological 
diseases/syndromes, such as meningitis/
encephalitis, cerebrovascular diseases, 
GBS, and Miller Fisher syndromes. 
Whether the association of these 
neurological findings to COVID-19 is 
causative or coincidental needs further 
study. For instance, the pathogenesis 
of GBS and Miller Fisher Syndrome 
patients is thought to originate from 
an aberrant immune response caused 
by the para- or post-viral process of the 
preceding microorganism infections 
such as Campylobacter jejuni or 
cytomegalovirus. Due to the temporal 
relationship, studies showed that GBS 
and Miller Fisher Syndrome might be 
associated with SARS-CoV-2 infection.14-16 
Therefore, intravenous immunoglobulin 
and plasmapheresis that were used as 
therapeutic agents in these patients 
resulted in favorable outcome.14-16 
A study about convalescent plasma 
therapy, that was collected from the 
donors who had recovered from SARS-
CoV-2 infections, in five severe COVID-19 
patients showed decreased viral load, 
improved symptoms, and decreased 
inflammatory biomarkers such as 
procalcitonin, C-reactive protein, and IL-
6.25 Thus, intravenous immunoglobulin, 
convalescent plasma therapy, or 
plasmapheresis using high SARS-CoV-2 
specific IgM-IgG antibodies or plasma 
derived from the donors who had 
recovered from SARS-CoV-2 infections 
should be more efficacious for patients 
with COVID-19-associated GBS or Miller 
Fisher Syndrome.
Limitations of this review were only 
searching the electronical databases 
from Medline/PubMed and continuing 
the search from the references list of 
the included studies. We only included 
studies that reported COVID-19 patient(s) 
directly from primary observations of 
the authors to make sure the objectivity 
of the reports, therefore we included 
all kinds of documents of observational 
studies, case series, case reports, letter 
to editors, and correspondences. Of the 
included studies, only three of them 
are retrospective, observational studies 
with level of evidence IIIb while the 
others are case series, case reports, letter 
to editors, and correspondences with 
level of evidence IV. Furthermore, the 
quantitative analysis was not performed 
in this study because of the insufficient 
data for pooled estimates and synthesis. 
Due to the rapid development of 
research in this area, many other studies 
regarding the neurological involvement 
in COVID-19 patients might be expected 
in the near future.
CONCLUSION
In conclusion, neurological 
involvement in COVID-19 ranges from 
neurological symptomatic complains 
to specific diseases such as meningitis/
encephalitis, cerebrovascular diseases, 
and neuromuscular diseases such as 
49
Ar Rochmah M, et al., Neurological findings in patients...
GBS and Miller Fisher syndrome. All 
health workers that take care of patients 
with COVID-19 and neurological diseases 
should be well aware of the possible 
neurological findings that might present. 
For diagnosis confirmation, supporting 
examinations could be performed and 
definitive treatments could be given 
with regards to protection policy and 
safety measure for the patients as 
well as the health workers. Further 
observational or cohort studies about 
neurological involvement in COVID-19 
patients are necessary to be performed 
in a larger number of patients with 
multicenter basis. In addition, studies to 
elucidate the definitive pathophysiology 
of neurological involvement in COVID-19 
are also necessary in conjunction with 
the promising therapeutic agents for the 
patients.
ACKNOWLEDGEMENT
We would like to thank all the staffs 
of Department of Neurology, Faculty of 
Medicine, Public Health, and Nursing 
Universitas Gadjah Mada for their 
supports upon the writing of this review. 
We would like to deliver our deepest 
gratitude to Cochrane Indonesia and 
Clinical Epidemiology and Biostatistics 
Unit, Faculty of Medicine, Public Health, 
and Nursing Universitas Gadjah Mada 
for assisting in the Methodology.
REFERENCES
1. Dadax Limited. Corona virus. 
2020. Available from: https://www.
worldometers.info/coronavirus/
2. Gugus Tugas Pecepatan Penanganan 
COVID-19. COVID-19. 2020. https://
www.covid19.go.id/
3. Guan W, Ni Z, Hu T, Liang WH, Ou CQ, 
He JX, et al. Clinical characteristics of 
coronavirus disease 2019 in China. N 
Engl J Med 2020; 382:1708-20. 
https://doi.org/10.1056/NEJMoa2002032
4. Vaira LA, Salzano G, Deiana G, De Riu 
G. Anosmia and ageusia: common 
findings in COVID-19 patients. 
Laryngoscope. 2020. 
https://doi.org/101002/lary.28692.
5. Mao L, Jin H, Wang M, Yu E, Chen S, 
He Q, et al. Neurologic manifestations 
of hospitalized patients with 
coronavirus disease 2019 in Wuhan, 
China. JAMA Neurol 2020. E1-E8.
h t t p s : / / d o i . o r g / 1 0 . 1 0 0 1 /
jamaneurol.2020.1127
6. Hutton B, Salanti G, Caldwell 
DM, Chaimani A, Schmid CH, 
Cameron C, et al. The PRISMA 
extension statement for reporting 
of systematic reviews incorporating 
network meta-analyses of health 
care interventions: checklist and 
explanations. Ann Intern Med 2015; 
162(11):777-84.
https:/ /www.cebm.net/2009/06/
oxford-centre-evidence-based-
m e d i c i n e - l e v e l s - e v i d e n c e -
march-2009/
7. Moriguchi T, Harii N, Goto J, Harada 
D, Sugarawa H, Takamino J, et al. A 
first case of meningitis / encephalitis 
associated with. Int J Infect Dis 2020; 
94:55–8. 
https://doi.org/10.1016/j.ijid.2020.03.062
8. Ye M, Ren Y, Lv T. Encephalitis as a 
clinical manifestation of COVID-19. 
Brain Behav Immun 2020; S0889-
1591(20):30465-7. 
https://doi.org/10.1016/j.bbi.2020.04.017
9. Duong L, Xu P, Liu A. 
Meningoencephalitis without 
respiratory failure in a young female 
patient with COVID-19 patient in 
Downtown Los Angeles, early April 
2020. Brain Behav Immun 2020; 
S0889-1591(20):30509-2. 
https://doi.org/10.1016/j.bbi.2020.04.024
10. Yin R, Lv T, Yin R, Hospital H, Feng 
W, Hospital H, et al. Concomitant 
neurological symptoms observed in 
a patient diagnosed with coronavirus 
disease 2019.J Med Virol 2019; 0–1. 
https://org.org/10.1002/jmv.25888.
11. Helms J, Kremer S, Merdji H, Clere 
50
J Med Sci, Volume 52, Number 3 (SI), 2020, Juli: 37-50
Jehl R, Schenck M, Kummerlen C, 
et al. Neurologic features in severe 
SARS-CoV-2 infection. N Engl J Med 
2020; NEJMc2008597
https//doi.org/10.1056/NEJMc2008597
12. Li Y, Wang M, Zhou Y, Chang J, Xian Y, 
Mao L, et al. Acute cerebrovascular 
disease following COVID-19: a single 
center, retrospective, observational 
study. Lancet. 2020;19. 
13. Zhao H, Shen D, Zhou H, Liu J, Chen S. 
Guillain-Barré syndrome associated 
with SARS-CoV-2 infection: causality 
or coincidence? Lancet Neurol 2019; 
19(5):383–4. 
http://dx.doi.org/10.1016/S1474-
4422(20)30109-5
14. Toscano G, Palmerini F, Ravaglia 
S, et al. Guillain-Barré Syndrome 
associated with SARS-CoV-2. N Engl J 
Med, 2020.NEJMc2009191.
h t t p : / / d x . d o i . o r g / 1 0 . 1 0 5 6 /
NEJMc2009191
15. Gutiérrez-ortiz C, Méndez A, 
Rodrigo-Rey S, San Pedro-Murillo E, 
Bermerjo-Guerrero L, Gardo Manas 
R, et al. Miller Fisher syndrome and 
polyneuritiscranialis in COVID-19. 
Neurology2020;241. 
h t t p s : / / d x . d o i . o r g / 1 0 . 1 2 1 2 /
WNL.0000000000009619.
16. Lu L, Xiong W, Liu D, Liu J, Yang D, 
Li N, et al. New-onset symptomatic 
seizure and risk factor in corona 
virus disease 2019: a retrospective 
multicenter study. Epilepsia 2020. 
https://dx.doi.org/10.1111/epi.16524.
17. Poyiadji N, Shahin G, Noujai D, Stone 
M, Patel S, Griffith B, et al. COVID-
19-associated acute hemorrhagic 
necrotizing encephalopathy: CT 
and MRI features. Radiology 2020; 
201187. 
h t t p s : / / d x . d o i . o r g / 1 0 . 1 1 4 8 /
radiol.2020201187
18. Wang Z, Xu X. scRNA-seq profiling of 
human testes reveals the presence of 
the ACE2 receptors target for SARS-
CoV-2 infection in spermatogonia, 
leydig and sertoli cells. Cells 2020; 
9(4):920.
h t t p : / / d x . d o i . o r g / 1 0 . 3 3 9 0 /
cells9040920 
19. Hamming I, Timens W, Bulthuis 
M, Lely AT, Navis GJ, Van Goor 
H. Tissue distribution of ACE2 
protein, the functional receptor for 
SARS coronavirus. A first step in 
understanding SARS pathogenesis. J 
Pathol 2004; 203(2):631–7.
https://doi.org/10.1002/path.1570
20. Li YC, Bai WZ, Hashikawa T. The 
neuroinvasive potential of SARS-
CoV-2 may play role in the respiratory 
failure of COVID-19 patients. J Med 
Virol 2020. 
http://doi.org/10.1002/jmv.25728.
21. Amiral J, Vissac AM, Seghatcian. 
COVID-19, induced activation of 
homeostasis, and immune reactions: 
Can an auto-immune reaction 
contribute to the delayed severe 
complications observed in some 
patients? TransfusApher Sci 2020; 
102804. 
h t t p s : / / d o i . o r g / 1 0 . 1 0 1 6 / j .
transci.2020.102804
22. Merad M, Martin JC. Pathological 
inflammation in patients with 
COVID-19: a key role for monocytes 
aand macrophages. Nat Rev 
Immunol 2020.
23. Hou H, Wang T, Zhang B, Luo Y, Mao 
L, Wang F, et al. Detection of IgM 
and IgG antibodies in patients with 
coronavirus disease 2019. Clin Trans 
Immunol 2020; e1136. 
https://doi.org/10.1002/cti2.1136.
24. Shen C, Wang Z, Zhao F, Yang Y, Li J, 
Yuan J, et al. Treatment of 5 critically 
ill patients with COVID-19 with 
convalescent plasma. JAMA 2020; 
323(16):1582-9.
